SON-080

Phase 1/2Terminated

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Chemotherapy-induced Peripheral Neuropathy (CIPN)

Conditions

Chemotherapy-induced Peripheral Neuropathy (CIPN)

Trial Timeline

Oct 27, 2022 → Mar 17, 2024

NCT ID

NCT05435742

About SON-080

SON-080 is a phase 1/2 stage product being developed by Sonnet BioTherapeutics for Chemotherapy-induced Peripheral Neuropathy (CIPN). The current trial status is terminated. This product is registered under clinical trial identifier NCT05435742. Target conditions include Chemotherapy-induced Peripheral Neuropathy (CIPN).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05435742	Phase 1/2	Terminated	Oct 27, 2022	Mar 17, 2024	Chemotherapy-induced Peripheral Neuropathy (CIPN)

Competing Products

20 competing products in Chemotherapy-induced Peripheral Neuropathy (CIPN)

See all competitors

Product	Company	Stage	Hype Score
Granisetron	Kyowa Kirin	Phase 3	77
ONO-7746	Ono Pharmaceutical	Phase 1	33
ONO-2910 + Placebo	Ono Pharmaceutical	Phase 2	52
PROCRIT 40,000 IU QW + Placebo	Johnson & Johnson	Phase 2	52
Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine Placebo	Jiangsu Hengrui Medicine	Phase 3	77
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 2	52
Hetrombopag + Hetrombopag plus Placebo + Placebo	Jiangsu Hengrui Medicine	Phase 3	77
Hetrombopag + Matching placebo	Jiangsu Hengrui Medicine	Phase 3	77
Hetrombopag + Placebo	Jiangsu Hengrui Medicine	Phase 3	77
Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue Therapy	Merck	Phase 3	77
Fosaprepitant	Merck	Phase 2	52
Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonist	Merck	Phase 3	77
Fosaprepitant + Dexamethasone + 5HT3	Merck	Phase 2	52
aprepitant + Comparator: Placebo to aprepitant + dexamethasone + granisetron + dexamethasone	Merck	Phase 3	77
aprepitant + Comparator: ondansetron + Comparator: dexamethasone + Comparator: fosaprepitant dimeglumine + Comparator; Placebo (unspecified) + Comparator; Placebo (unspecified)	Merck	Phase 3	77
EMEND	Merck	Pre-clinical	23
Fosaprepitant Dimeglumine + 5-HT3 antagonist + Dexamethasone	Merck	Approved	85
ondansetron clinical trial formulation + ondansetron marketed formulation	Merck	Phase 1	33
Aprepitant + Palonosetron + Dexamethasone	Merck	Phase 2	52
Fosaprepitant 150 mg + Aprepitant 165 mg + Aprepitant 250 mg + Dexamethasone (12-8-16-16 mg) + Dexamethasone (12-8-8-16 mg) + Ondansetron + MK0999	Merck	Phase 1	33

Other Products from Sonnet BioTherapeutics

SON-1010Phase 1/2

SON-1010 (IL12-FHAB)Phase 1

SON-1010Phase 1